ARCHIVES

Cyramza-Docetaxel Combination Extends OS In Second-Line NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

Blincyto Demonstrates Response In Minimal Residual Disease ALL

December 26, 2014

FDA News: Tentative Approval Given IVAX Paxene; BMS Exclusivity Upheld

January 9, 1998

FASEB Urges Congress To Fund Stem Cell Research.

July 27, 2001

ASCO Conquer Cancer Foundation Awards $6 Million To Researchers

April 22, 2011

In Brief: Breast Cancer Diet Study Problems Resolved, Funding Resumed For Nutrition Coordinator

April 19, 1985

NIH Limits Salaries On Grants, Contracts ACS Clinical Awards Available For 1995

February 25, 1994